Cost Effectiveness of Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Heart Disease
Open Access
- 6 June 2002
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 346 (23) , 1800-1806
- https://doi.org/10.1056/nejm200206063462309
Abstract
Both aspirin and clopidogrel reduce the rate of cardiovascular events in patients with coronary heart disease. We estimated the cost effectiveness of the increased use of aspirin, clopidogrel, or both for secondary prevention in patients with coronary heart disease.Keywords
This publication has 36 references indexed in Scilit:
- Aspirin Use and All-Cause Mortality Among Patients Being Evaluated for Known or Suspected Coronary Artery DiseaseJAMA, 2001
- AspirinCirculation, 2000
- Antithrombotic Agents in Coronary Artery DiseaseChest, 1998
- Treatment and outcomes of acute myocardial infarction among patients of cardiologists and generalist physiciansArchives of internal medicine (1960), 1997
- Aspirin as a Therapeutic Agent in Cardiovascular DiseaseCirculation, 1997
- Aspirin in the Treatment of Acute Myocardial Infarction in Elderly Medicare BeneficiariesCirculation, 1995
- Aspirin as an Antiplatelet DrugNew England Journal of Medicine, 1994
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994
- A Hearty Endorsement for AspirinScience, 1994
- Secondary prevention of vascular disease by prolonged antiplatelet treatmentBMJ, 1988